W19128 - Bureau of Health Professions Licensure Notice of Opportunity

The Massachusetts Department of Public Health's Bureau of Health Professions Licensure (BHPL) is soliciting proposals for a comprehensive Toxicology Drug Screening Services contract for the Unified Recovery and Monitoring Program (URAMP). The procurement seeks qualified Drug Testing Management Companies (DTMCs) to administer a full-scale drug screening program serving approximately 500,000 licensed healthcare professionals across 21 licensing boards. Respondents must demonstrate extensive capabilities in enrollment, randomized testing, specimen collection, laboratory analysis, results reporting, and potential expert testimony. Key deliverables include developing robust processes for collecting specimens, conducting laboratory tests, maintaining data confidentiality, and providing comprehensive reporting mechanisms. Prospective vendors must submit detailed documentation demonstrating their experience, collection and testing processes, key staff qualifications, data protection protocols, fee structures, and relevant certifications. The contract solicitation timeline includes a deadline for written questions by October 23, 2024, with final proposals due on November 7, 2024. The anticipated contract term is up to five years, with potential for significant program expansion, potentially increasing caseload by up to 100% within the first three years.

The Notice of Opportunity does not explicitly indicate specific set-aside designations or restrictions for disadvantaged enterprises. The current DTMC has an existing agreement, but BHPL is actively seeking alternative vendors who can provide more cost-effective services to the Commonwealth. A unique aspect of this contract is that the selected DTMC will be responsible for collecting all fees directly from program participants, subject to BHPL's approval, with the department reserving the right to review the vendor's financial statements related to these collection activities. While specific budget ranges are not detailed in the documentation, the scope of services covering 500,000 licensed professionals suggests a substantial potential contract value. Vendors must be prepared to demonstrate comprehensive capabilities in toxicology screening, including maintaining high standards of accuracy, confidentiality, and professional conduct across a diverse range of healthcare licensing boards. The contract appears designed to support the Commonwealth's ongoing efforts to monitor and ensure the professional integrity of healthcare practitioners through rigorous and systematic drug screening processes.